KRT19 Knockout 769-P Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated by disruption of the KRT19 gene in the 769-P human renal cell carcinoma line. This heterogeneous loss-of-function model enables investigation of keratin 19 function in epithelial cell biology without the constraints of monoclonal selection, preserving genetic diversity relevant to tumor heterogeneity.
The 769-P cell line, derived from a primary clear cell renal cell carcinoma, serves as a well-characterized in vitro model for kidney cancer research. It retains epithelial features and key oncogenic alterations, making it suitable for studying renal carcinoma signaling, drug responses, and metastatic mechanisms. 769-P cells express simple epithelial keratins, including KRT8 and KRT18, the type II partners necessary for filament formation with KRT19.
KRT19 encodes keratin 19, a type I intermediate filament protein that heterodimerizes with KRT8 to provide mechanical integrity to epithelial cells. Beyond its structural role, KRT19 interacts with 14-3-3 and TRADD, modulating signal transduction. Its expression is regulated by EGF, TGF-??, p53, AP-1, and SP1, and it functions upstream of AKT1, MAPK3 (ERK1), and CTNNB1 (??-catenin). Through these interactions, KRT19 influences the PI3K-AKT-mTOR, MAPK/ERK, and Wnt/??-catenin pathways, as well as the E-cadherin/??-catenin complex, thereby contributing to epithelial-mesenchymal transition and cell migration.
In 769-P cells, KRT19 supports epithelial phenotype maintenance and modulates oncogenic signaling. Its CRISPR/Cas9-mediated knockout enables dissection of its role in renal carcinoma cell migration, invasion, and drug sensitivity. Given KRT19 overexpression in many carcinomas and its association with poor prognosis, this polyclonal model captures heterogeneous loss-of-function effects, more closely mirroring intratumoral variability. Comparison with parental cells allows identification of KRT19-dependent molecular changes, such as altered ERK or ??-catenin activity, that promote metastatic behavior.
These cells are suitable for Western blotting, RT-qPCR, and immunofluorescence to confirm KRT19 depletion and analyze interacting partners like KRT8. Functional assays include Transwell migration/invasion, wound healing, and MTT drug sensitivity tests, alongside flow cytometry for EMT marker profiling. Applications extend to studying epithelial cancer biology, identifying biomarkers for carcinomas, and screening compounds targeting KRT19-linked pathways. For further information, contact Ascent Research.
